BJC reports最新文献

{"title":"Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians.","authors":"Maria Frances Coakley, Javier Pascual, Seamus O'Reilly","doi":"10.1038/s44276-025-00181-y","DOIUrl":"10.1038/s44276-025-00181-y","url":null,"abstract":"","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"64"},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer.","authors":"Vasily Giannakeas, Steven A Narod","doi":"10.1038/s44276-025-00180-z","DOIUrl":"10.1038/s44276-025-00180-z","url":null,"abstract":"","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"63"},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective study.","authors":"Amer Saleh, Viktor Grünwald, Thomas Hilser, Christopher Darr","doi":"10.1038/s44276-025-00178-7","DOIUrl":"10.1038/s44276-025-00178-7","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced renal cell carcinoma (RCC), but their use is associated with immune-related adverse events, including hepatic adverse events (irHAEs).</p><p><strong>Methods: </strong>We retrospectively analysed 105 RCC patients treated with ICIs as first-line therapy between 2018 and 2023 at the University Hospital of Essen. Patients were categorized by the development of irHAE, defined per CTCAE grading v5.0. Multivariable logistic regression was used to identify risk factors, while Kaplan-Meier survival analyses evaluated PFS and OS.</p><p><strong>Results: </strong>Among the cohort, 16.19% (n = 17) developed irHAE, while 8.57% (n = 9) experienced higher-grade events. Combination therapy with tyrosine kinase inhibitors (TKIs) was associated with a higher likelihood of irHAE (OR: 7.69, p = 0.037) compared to ICI-only regimens, with cabozantinib showing a significantly shorter time to onset (35 vs. 84 days; p < 0.001). Patients with a BMI ≥ 25 had a significantly increased risk (p = 0.011). Differences in PFS (18.63 vs. 19.87 months; p = 0.099) and OS (27.80 vs. 23.87 months; p = 0.36) were not statistically significant.</p><p><strong>Conclusions: </strong>The combination of ICI with TKI posed higher risks for irHAE in RCC patients. While survival outcomes were unaffected, the results underscore the need for tailored monitoring and management. Prospective studies are warranted to refine therapeutic approaches.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"61"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145077057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia.","authors":"Brian J Altman, Po-Ju Lin, Lindsey J Mattick, Elliot H Outland, Javier Bautista, Chin-Shang Li, Umang Gada, Kristina M Morris, Amelia M Knudsen-Clark, Daniel Mwangi, Rachel E DeRollo, Amber S Kleckner, Ian R Kleckner, Nikesha J Gilmore, Benjamin T Esparaz, Amarinthia Curtis, Alison Conlin, Gianni Monaco, Jacob J Hughey, Karen M Mustian","doi":"10.1038/s44276-025-00176-9","DOIUrl":"10.1038/s44276-025-00176-9","url":null,"abstract":"<p><strong>Background: </strong>Insomnia is a toxicity of cancer and treatment for survivors without an objective biochemical measure. Circadian rhythms are 24-h cycles that influence physiologic processes including sleep, and disrupted rhythms may contribute to insomnia. Here, we use BloodCCD to assess circadian rhythms from RNA-sequencing of blood from cancer survivors with insomnia from the YOCAS-II trial. YOCAS-II aimed to determine whether YOCAS©® yoga or cognitive behavioral therapy for insomnia (CBT-I) improved insomnia in survivors compared with a behavioral placebo. We hypothesized that circadian rhythms are disrupted in survivors, and that insomnia severity correlates with the degree of circadian disruption.</p><p><strong>Methods: </strong>BloodCCD was developed to biochemically assess circadian rhythms in blood. It was adapted from the previously published Clock Correlation Distance (CCD) and uses a correlation matrix of 42 genes known to oscillate throughout the day in blood.</p><p><strong>Results: </strong>Cancer survivors had higher (worse) BloodCCD scores, indicating disrupted circadian clock, compared to healthy individuals. Furthermore, insomnia severity correlated with worse BloodCCD, and those in the YOCAS and behavioral placebo arm showed significant correlation between BloodCCD score and insomnia.</p><p><strong>Conclusions: </strong>BloodCCD shows promise as a biomarker to biochemically detect disrupted circadian rhythms in cancer survivors, and as an indicator for insomnia severity.</p><p><strong>Clinical trial identifier: </strong>NCT02613364.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"60"},"PeriodicalIF":0.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cataloguing and evaluating Irish health data resources for primary care cancer research.","authors":"Oisín Brady Bates, Alexander Carroll, Caoimhe Hughes, Collette Murtagh, Benjamin Jacob, Kathleen Bennett, Patrick Redmond","doi":"10.1038/s44276-025-00170-1","DOIUrl":"10.1038/s44276-025-00170-1","url":null,"abstract":"<p><strong>Background: </strong>In Ireland, cancer is a leading cause of mortality. Optimising primary care cancer research is crucial for better patient outcomes and healthcare policies. This study identifies Irish health data resources relevant to primary care cancer research, addressing a gap in understanding data availability and utility to enhance cancer care.</p><p><strong>Methods: </strong>We conducted a comprehensive review of Irish health data resources across multiple platforms, including a broad data search, expert consultations, literature review, and data synthesis. An expert roundtable refined our findings.</p><p><strong>Results: </strong>Our review identified 39 data resources, including national registries, biobanks, and health system audits. We noted varying levels of data accessibility and comprehensiveness, with several datasets offering significant potential. Emergent themes focused on data quality and practical utility to address specific primary care cancer research questions.</p><p><strong>Conclusion: </strong>This review provides a foundational resource for primary care cancer researchers in Ireland, highlighting available data, potential gaps, and challenges. The resulting data catalogue will guide future research, supporting evidence-based strategies and advancing health informatics and cancer research.</p><p><strong>Highlights: </strong>This comprehensive review identifies and evaluates a diverse range of Irish health data resources, establishing a foundational catalogue for advancing primary care cancer research in Ireland. The study highlights significant gaps in data accessibility and utility, underlining the need for enhanced data integration and linkage to improve research outcomes and healthcare strategies. Our findings provide a roadmap for policymakers and researchers, recommending the optimisation of existing datasets to support evidence-based cancer care strategies and inform future healthcare improvements in Ireland.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"59"},"PeriodicalIF":0.0,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex disparity in survival outcomes of advanced gastric adenocarcinoma.","authors":"Minggui Pan, Meng M Tong, Jack Stover, Tina Huang, Arun Dang, Chen Jiang, Ninah S Achacoso, Jeffrey Bien, Aleyda V Solorzano, Pamela Tse, Elaine Chung, Vishnu P Kanakaveti, Dean Felsher, George A Fisher, Sachdev Thomas, Laurel Habel","doi":"10.1038/s44276-025-00173-y","DOIUrl":"10.1038/s44276-025-00173-y","url":null,"abstract":"<p><strong>Purpose: </strong>To examine potential overall survival (OS) differences between males and females with advanced gastric (GAC), gastroesophageal junction (GEJAC) and esophageal (EAC) adenocarcinoma.</p><p><strong>Patients and methods: </strong>The study included patients from Kaiser Permanente Northern California with de novo metastatic or relapsed EAC, GEJAC and GAC. We used Cox regression modeling to examine association of sex with OS adjusting for demographics, performance status, Charlson comorbidity index, histology (Lauren's classification), receipt of chemotherapy, and HER2 amplification or overexpression, p53, KRAS, CDKN2A, PIK3CA co-mutations and MYC amplification.</p><p><strong>Results: </strong>Of 875 total eligible patients, 426 had GAC, of whom 224 were male and 202 were female. Among patients with GAC, males had better OS than females (HR = 0.73; [95% CI, 0.59-0.92]), and this OS difference was preserved across the molecular subgroups except mutKRAS. Intriguingly, among GAC patients with a p53 mutation, males versus females had better OS if tumor carried a non-gain-of-function mutation (non-GOF, HR = 0.59; [95% CI, 0.40-0.85]) but worse OS if tumor carried gain-of-function mutation (GOF, HR = 1.80; [95% CI, 0.83-3.99]). Sex was not associated with OS among patients with GEJAC (HR = 1.14); (95% [CI, 0.77-1.67]) or EAC (HR = 1.0; [95% CI, 0.57-1.74]). These results remained similar when separate analyses were performed among patients who received and among patients who did not receive chemotherapy.</p><p><strong>Conclusions: </strong>Males had better OS than females among patients with advanced GAC. In addition, among GAC patients with a mutp53, sex and OS association was inversely driven by the presence of GOF versus non-GOF. Our data reveal a previously unappreciated sex disparity in survival outcomes among patients with advanced GAC. If confirmed, this finding could have important implications for clinical practice and for further understanding the biology of GAC.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"58"},"PeriodicalIF":0.0,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trials.","authors":"Hoda Nemat, Martin Orr, Lucy Barrow, Bindu Raobaikady, Sheila Matharu, Lisa Scerri, Udai Banerji, Ceire Costelloe","doi":"10.1038/s44276-025-00165-y","DOIUrl":"10.1038/s44276-025-00165-y","url":null,"abstract":"<p><strong>Background: </strong>Phase I trials include patients with metastatic cancer and complex health conditions. Understanding baseline comorbidity and demographic features is critical to improving trial design.</p><p><strong>Methods: </strong>We used electronic patient records to study the association of comorbidity, polypharmacy, and demographic factors on trial recruitment, time on trial, and health service utilisation.</p><p><strong>Results: </strong>A cohort of 1671 patients was considered for allocation to a phase I study, of whom 518 patients were recruited to a phase I study and 1153 patients were not. A multivariable analysis revealed polypharmacy was associated with lower recruitment to phase I trials with an odds ratio of 0.95 (95% CI: [0.92, 0.99], p = 0.01), and a greater number of emergency admissions with a risk ratio of 1.1 (95% CI: [1.03, 1.17], p = 0.01). Interestingly, comorbidity was not associated with lower recruitment but was associated with a lower time on trial with a hazard ratio of 0.75 (95% CI: [0.62, 0.90], p ≤ 0.001). Demographic factors, including ethnicity, distance of residence from the hospital, and index of multiple deprivation, did not significantly influence these parameters.</p><p><strong>Conclusion: </strong>Polypharmacy and comorbidity should be considered both in the design of phase I oncology trials and in planning for healthcare utilisation during these trials.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"57"},"PeriodicalIF":0.0,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United Kingdom.","authors":"Szeyi Ng, Lucy S Kilburn, Hilary Stobart, Lesley Stephen, Indrani S Bhattacharya, David A Cameron, Rebecca Lewis, Stuart A McIntosh, Carlo Palmieri, Catherine Towns, Charlotte E Coles, Judith M Bliss","doi":"10.1038/s44276-025-00172-z","DOIUrl":"10.1038/s44276-025-00172-z","url":null,"abstract":"<p><strong>Background: </strong>The impact of cancer transcends physical health, affecting mental wellbeing, financial stability, and ability to perform daily tasks, influencing not only patients but also the broader community.</p><p><strong>Methods: </strong>Online anonymous surveys (24/01/2023-03/03/2023) were disseminated via charities to individuals treated for breast cancer in the UK and their carers. Multivariable ordered logistic regression models were used to investigate demographic, cancer-related and employment factors associated with physical, wellbeing and financial Quality-of-Life (QoL).</p><p><strong>Results: </strong>470 and 136 participants reported primary (PBC) and metastatic (MBC) breast cancer, respectively. 27% PBC and 35% MBC participants reported experience of financial problems. 17% PBC and 47% MBC participants reported trouble fulfilling caring responsibilities at the time of survey completion. For PBC participants, reports of financial problems were associated with difficulties seeking help for physical or wellbeing issues, which were associated with worse physical and wellbeing QoL. Financial problems, and other challenges were more commonly reported among MBC participants. These factors may impact QoL similarly, so there was no evidence of specific explanatory factors for MBC participants.</p><p><strong>Conclusions: </strong>Better understanding of wider impact of breast cancer could lead to better policy and support. Future clinical trials should incorporate more comprehensive assessment of breast cancer's wider effects.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"55"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer survival in a rural setting in the Busoga Region of Uganda.","authors":"Rasmus Kallestrup, Katinka Bolette Lorentzen, John Mwayi, Joanita Mbabazi, Per Kallestrup, Troels Alnor Einarson","doi":"10.1038/s44276-025-00166-x","DOIUrl":"10.1038/s44276-025-00166-x","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) poses a significant health challenge globally. While high-income countries benefit from robust healthcare systems, sub-Saharan Africa (SSA) faces elevated BC mortality rates. Despite extensive research on BC survival, rural populations in SSA, including Uganda, remain underrepresented in scientific literature.</p><p><strong>Methods: </strong>We performed a cohort study aiming to bridge this gap by investigating BC survival among the rural population of the Busoga Region, Uganda, leveraging data from patient registers of Rays of Hope Hospice Jinja. Using a retrospective survival study design, we estimated 1-, 3-, and 5-year survival rates (SRs) for BC cases from 2016 to 2022 via Kaplan-Meier plots.</p><p><strong>Results: </strong>Our compiled diagnosis model found a 1-year SR of 57.7% (95%-CI: 51.6-64.4), a 3-year SR of 19.1% (95%-CI: 13.9-26.1) and a 5-year SR of 16.3% (95%-CI: 11.4-23.4). Our biopsy-confirmed documented date model finds a 1-year SR of 66.3% (95%-CI: 56.3-78.1) and a 3-year SR of 31.3% (95%-CI: 20.6-47.6). We found age ≥50 and higher education to be positively correlated with survival and a clinical presentation of advanced-stage disease to be negatively correlated.</p><p><strong>Conclusions: </strong>This cohort study implies that rural populations have lower BC survival and hold implications for interventions to improve BC outcomes in SSA.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"56"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of consecutive patients of oropharyngeal cancer treated with radical radiotherapy.","authors":"Ashwini Budrukkar, Sheetal R Kashid, Monali Swain, Sarbani Ghosh Laskar, Neha Mittal, Manoj Mahimkar, Ajay Sasidharan, Asawari Patil, Usha Patel, Vedang Murthy, Tejpal Gupta, Vijay Patil, Amit Joshi, Vanita Noronha, Shwetabh Sinha, Anuj Kumar, Nandini Menon, Munita Bal, Kumar Prabhash, Jai Prakash Agarwal","doi":"10.1038/s44276-025-00164-z","DOIUrl":"10.1038/s44276-025-00164-z","url":null,"abstract":"<p><strong>Objectives: </strong>Given the wide variation in the incidence of Human Papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC), we aimed to evaluate the prevalence of HPV and assess treatment outcomes in patients with OPSCC treated with definitive radiotherapy (RT) with or without chemotherapy (CT) at a single institution in India.</p><p><strong>Methods: </strong>Consecutive patients of OPSCC treated with definitive RT + /-CT in a tertiary care centre from January 2013 to December 2017 were analyzed. Kaplan-Meier method was used for survival analysis, and Log-rank test was used for univariate analysis.</p><p><strong>Results: </strong>Six-hundred-thirty patients with OPSCC were treated with definitive RT + /-CT. The median age was 56 years (IQR 48-62). As per American Joint Committee on Cancer (AJCC) 7^th edition, 24 (3.8%) were stage I, 63 (10%) were stage II, 113 (18%) were stage III, 375 (59.5%) were stage IVA, and 55 (8.7%) were stage IVB. HPV status was known for 500 patients of which 55 (11%) were p16 immunohistochemistry positive. At a median follow-up of 73.3 months (IQR 58-89), 5-year local control (LC), loco-regional control (LRC), disease-free-survival (DFS) and overall survival (OS) were 48.1%, 35.6%, 29.2% and 34.5%, respectively. HPV-positive cohort showed significantly better outcomes compared to HPV-negative cohort with 5-year LC, LRC, DFS, OS of 84.4% vs 43.5% (p < 0.001), 71.3% vs 31.8% (p < 0.001), 63.9% vs 26.1% (p < 0.0001) and 69.1% vs 31.9% (p < 0.001) respectively.</p><p><strong>Conclusion: </strong>The prevalence of HPV-positive OPSCC by p16 IHC was only 11% in our cohort. The outcomes of HPV-negative cancers are inferior when compared to HPV-positive cancers for a particular stage. Thereby justifying the need for development of treatment-intensifying strategies to improve the inferior outcomes.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"54"},"PeriodicalIF":0.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}